Quivive Pharma, Inc

Round A investments of $12.5 million from accredited long term Investor partners

Problem: There is an opioid overdose and addiction crisis in the US. Everyday 135 people overdose and die from respiratory arrest; this places an economic burden of $95.3 Billion dollars per year.

Solution: The common sense approach is to treat the opioid side effect of respiratory depression with a respiratory stimulant. QEV-817 is an inseparable opioid + respiratory stimulant combination that treats pain and prevents abuse / addiction by averting overconsumption. QEV-817 has the FDA 505(b)2 approval path and is **set for fast track and expedited review**, as per FDA meeting of Oct 17, 2017. IND submission to the FDA is slated within 2018 and **NDA approval is anticipated in 2021.**

Market: Over 100 million people use opioids daily. 257 million opioid prescriptions were written in 2015. In 2015, the opioid market was $9.57 Billion per year (IMS Quintiles). By 2025, the opioid market is slated to be $34.96 Billion per year (Grandview Research Inc). The goal of Quivive is to substitute **ALL** current oral immediate release (IR) opioids without abuse deterrent formulations (ADF) to **QEV-817**, an oral IR opioid with (ADF), to safely treat **ALL** acute pain.

Intellectual Property: U.S.Patent no.10004749 has been granted from 2 patent families. Any opioid, benzodiazepine, barbiturate, or sleeping pill delivered in combination with the respiratory stimulant orally, transdermally, transmucousally is protected by the patent. **This generates a future pipeline of 20-25 drugs with additional patent filings to include claims for respiratory stimulant combinations with Fentanyl Patch, Oxycodone, Alprazolam, etc.**

Business Model / Commercialization: 70% of physicians are employed and can only prescribe drugs from an approved formulary. By having pre-marketed the value proposition of substituting **all** unsafe oral (IR) opioids **without** (ADF) with QEV-817, ExpressScripts, OPTUM and AnthemBlueCross Connecticut have indicated that QEV-817 would be placed on TIER 1 formularies. This would allow quick market penetrance and accelerate the return on investment. New drugs because of their price are almost always introduced on TIER 3 and seldom meet sales goals.

Opportunity: QEV-817 is at phase 1B and will soon open an IND to start clinical trials. Quivive is seeking to close Round A investments of $12.5 million from a limited number of accredited long term Investor partners. QEV-817 is expected to obtain NDA approval in 2021, for which an estimated $35 million more is needed to complete the rest of the project

Executive Leadership

John Hsu MD,	CEO, Founder of Quivive Pharma, IPill, IMTH REIT
Peter Rix DABT,	CSO, Safety toxicologist. Exited out of Aragon and Saragon.
Gary Seelhorst, MBA	Senior VP of Business development. Took Imprimis public

Advisory Board

Robert Rappaport, MD	Former FDA Director of DAAAP
Brian Harvey, MD, PHD,	Former FDA Director of Gastroenterology
Lynn Webster, MD,	Past President American Pain Society
Camargo pharma services,	Regulatory 505(b)2 support
Joseph Cotten MD, PhD,	Clinical Support Harvard Medical

John Hsu MD
CEO Founder www.quivivepharma.com
John.Hsu@quivivepharma.com
(626) 695-5985